Biological Applications of a Chimeric Probe for the Assessment of Galectin-3 Ligands

Abstract

β1–6 branching of N-linked oligosaccharides has been correlated with the progression of different cancers. The leukoagglutinins of Phaseolus vulgaris (L-PHA) have been used to study this pattern of glycosylation whose biological significance is incompletely understood. The animal lectin, galectin-3, also binds to structures recognized by L-PHA. To develop a functional tool for the in situ identification of this pattern of glycosylation, human galectin-3 was fused to bacterial alkaline phosphatase (gal3/AP). Gal3/AP recognized both A and B blood group saccharides (B>A) and lactosamine derivatives. Gal3/AP recognition depended at least in part on the N-linked oligosaccharides of different glycoproteins. The presence and distribution of galectin-3 ligands were analyzed in both murine and human normal and tumor samples. Loss of apical expression of galectin-3 ligands was commonly found in carcinomas. Endothelial and inflammatory cells were enriched in galectin-3 ligands as compared with tumor cells; thus, gal3/AP is a suitable tool for studying tumor micro-environments. Comparative analysis of both gal3/AP and L-PHA binding patterns indicated that although similar, these patterns are not identical. The probe developed was useful for several immunoenzymatic assays and will allow the physiological and clinical significance of the expression pattern of galectin-3 ligands to be established. This manuscript contains online supplemental material at http:/www.jhc.org. Please visit this article online to view these materials. (J Histochem Cytochem 55: 1015–1026, 2007)

Keywords

galectin-3 galectin-3 ligands L-PHA aberrant glycosylation

Galectins are a growing family of β-galactoside-binding animal lectins (Liu and Rabinovich 2005). Galectin-3 is unique within this family because it is composed of three distinct structural domains (Agrwal et al. 1993): (1) an N-terminal domain of 12 amino acids containing the determinant of its cellular targeting (Gong et al. 1999); (2) a repetitive collagen-like sequence rich in proline, glycine, and tyrosine; and (3) the COOH-terminal domain, a globular structure encompassing the carbohydrate-recognition domain (CRD), which is evolutionarily conserved in all galectins (Yang et al. 1998). Galectin-3 is present in the cytoplasm and in the nucleus, regulating important cellular processes including apoptosis (Akahani et al. 1997; Takenaka et al. 2004), cell growth (Lin et al. 2002; Mazurek et al. 2005), and alternative splicing (Park et al. 2001). Galectin-3 is also secreted where it can interact with extracellular matrix molecules such as laminin (Ochieng and Warfield 1995), elastin (Ochieng et al. 1999), fibronectin (Sasaki et al. 1998), and cell surface glycoproteins including integrins (Fukumori et al. 2003), CEA (Cvejic et al. 2000), CD66 (Feuk-Lagerstedt et al. 1999), and 90/Mac-2BP (Inohara et al. 1996).

Galectin-3 is expressed in a variety of cells including epithelial and endothelial cells (Glinsky et al. 2001; Lin et al. 2002; Mengwasser et al. 2002; Khaldoyanidi et al. 2003), activated macrophages (Dong and Hughes 1997; Kim et al. 2003), and dendritic cells (Swarte et al. 1998; Vray et al. 2004). A potential role for galectin-3 in inflammation has been suggested by experiments using galectin-3 null mice (Colnot et al. 1998; Hsu et al. 2000; Bernardes et al. 2006). In fact, recent evidence suggests that galectin-3 is a pro-inflammatory protein (Colnot et al. 1998; Hsu et al. 2000). It downregulates interleukin (IL)-5 gene expression in human eosinophils (Cortegano et al. 1998), activates NADPH oxidase (Almkvist et al. 2004), stimulates superoxide production from neutrophils (Yamaoka et al. 1995), and promotes monocyte chemotaxis (Sano et al. 2000). In the extracellular space, galectin-3 may act as a de-adhesion molecule, as shown in the interaction of thymocytes and thymic microenvironmental cells (Villa-Verde et al. 2002) and stimulate cell migration (Silva-Monteiro et al. 2007) and cell death (Stillman et al. 2006; Silva-Monteiro et al. 2007). These diverse galectin-3 functions seem related to the ligands engaged in different cell types and tissues.

As a lectin, galectin-3 recognizes preferentially polylactosamines found in tri- or tetra-antennary N-linked oligosaccharides. Biosynthesis of these structures depends on the activity of N-acetylglucosaminyltransferase V (Mgat-5). Mgat-5 is responsible for the β1,6 branching of N-linked oligosaccharides and has been described as a transforming gene product (Demetriou et al. 1995; Yamamoto et al. 2000; Handerson and Pawelek 2003). The plant lectin leukoagglutinin (L-PHA) has been used for the identification of the Mgat-5-dependent glycosylation pattern (Dennis and Laferte 1989). Both L-PHA and galectin-3 have similar binding specificities (Demetriou et al. 2001). The former has been used as a probe for histochemical studies of human tumors from different origins (Sivridis and Agnantis 1996; Suzuki et al. 1999). To exploit the functional significance of this aberrant pattern of glycosylation, we have generated a novel probe based on human galectin-3 itself fused with the gene of the bacterial alkaline phosphatase (AP). We have therefore constructed a bifunctional probe, which has the binding activity of human galectin-3 and displays the enzymatic activity of AP, thus allowing for the in situ identification of galectin-3 ligands in tissue sections, in addition to its use in a variety of immunochemical methods.

Materials and Methods

Materials

All reagents were purchased from Sigma (St Louis, MO) unless stated otherwise and were of analytical grade or higher. Either biotin- or digoxigenin-conjugated lectins used were L-PHA, Galanthus nivalis agglutinin, and peanut agglutinin, all purchased from Roche (Mannheim, Germany). Antidigoxigenin antibodies were purchased from Roche. Laminin-1 was a kind gift from Dr. Vilma Martins, Ludwig Institute for Cancer Research, São Paulo, Brazil.

Cells and Antibodies

Cell lines used were the murine melanoma B16-F10 and two sarcoma cell lines (CCR2 and Σ12). Murine melanomas were cultured in RPMI 1640, supplemented with 10% fetal calf serum (Gibco; Grand Island, NY) in a humidified incubator equilibrated with 5% CO₂ at 37C. CCR2 and Σ12 cells were cultured in DMEM supplemented with 10% fetal calf serum under the same conditions. Cells were harvested at subconfluence with trypsin and EDTA. To inhibit the processing of N-linked glycans, cells were treated with the α-mannosidase inhibitors 1-deoxymannojirimycin (dMN, 1 mM for 24 hr) or swainsonine (SW, 1 μg/ml for 48 hr).

The hybridoma-secreting rat anti-galectin-3 monoclonal antibody (TIB166, M3/38) was purchased from the American Tissue Culture Collection (ATCC; Manassas, VA) and was maintained in DMEM supplemented with 10% fetal calf serum under culture conditions. Supernatants were harvested, pooled, and tested for activity and specificity using a panel of cell extracts and the purified recombinant protein galectin-3. Rabbit anti-bacterial AP was purchased from Chemicon (Temecula, CA), anti-rat IgG horseradish peroxidase (HRP) conjugates were from KPL, Kirkegaard and Perry Laboratories (Gaithersburg, MD), and anti-rabbit IgG HRP conjugates were from Sigma.

In Vivo Experiments

Female Balb-c and C57bl/6 mice (6–8 weeks old) were used in the experiments. Animals were housed under controlled environmental conditions in 12-hr light cycles. Samples from normal murine tissues (e.g., thymus) were collected after approval by the University of São Paulo Medical School Ethics Committee for Research (both on animals and humans). When indicated, animals were inoculated with either the melanoma cell line (B16F10, isogenic to C57bl/6 mice) or the CCR2 sarcoma cell line (isogenic to Balb-c mice). Animals were sacrificed when tumors reached 0.5 cm³. Tumors were then excised and processed for histopathological analysis.

Construction of the Hybrid Galectin-3 Molecule

The human galectin-3 (gal3) gene was cloned in the pLIP6-GN vector, which encodes the AP gene, phoA. This vector presents unique restriction sites, SfiI and NotI, between codons coding for residues +6 and +7 of mature AP, thus allowing the periplasmic exportation of the fusion protein and correct processing of the signal peptide, after induction of the tac promoter with isopropyl 1-thio-β-D-galactopyranoside (IPTG). This facilitates disulfide bond formation, solubility, extraction, and purification of proteins (Uhlen and Moks 1990). In the empty pLIP6-GN vector, the phoA gene is out of frame and advantageously restored upon cloning of the foreign DNA insert, permitting a visual selection of blue colonies on BCIP agar plates (Gillet et al. 1992). In addition, this vector also has an ampicillin-resistance cassette (amp^r). AP produced by this system presents two mutations resulting in a variant enzyme with enhanced enzymatic activity (Muller et al. 2001). The pLIP5-GN vector was used to obtain a positive AP control because its phoA gene is in-frame, expressing after induction the variant active enzyme alone.

The gal3 gene was PCR amplified from the pKK322-Gal3 clone using primer gal3NTSfi (5′-attagggcccagccggccgcagacaatttttcg-3′) and primer gal3CTNot (5′-gagaggcggccgctatcatggtatatga-3′), which added a SfiI and a NotI restriction site at the 5′ and 3′ of the PCR product, respectively. The amplification product was digested with SfiI and NotI restriction endonucleases and subsequently ligated into the pLIP6-GN vector previously cleaved with the same enzymes (see scheme in Figure 1A). The ligation product was used to transform E. coli DH5α, and the bacteria were seeded in TSB–agar plates (tryptone 20 g/L, yeast extract 5 g/L, NaCl 5 g/L, and K₂HPO₄ 2.5 g/L, pH 7.5, 1.5% agar) containing 100 μg/ml ampicillin, 100 μM IPTG, and 40 mg/ml BCIP. The phosphate in the media inhibited the expression of the bacteria phoA gene, whereas the IPTG induced the vector tac promoter, permitting the expression of AP fusion proteins that hydrolyzed the BCIP substrate resulting in blue colonies. Ampicillin-resistant blue colonies were PCR-screened using the pLIP forward sequencing primer (5′-CAAAGCACTATTGCACTGGC-3′) and the reverse gal3CTNot primer used in the amplification of the gal3 gene. A positive clone was selected and confirmed after complete sequencing of the gal3 gene and upstream AP coding fragments. DNA sequencing was carried out using an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems; Foster City, CA).

Figure 1

Construction and expression of a chimeric probe containing both galectin-3 and alkaline phosphatase (AP) activities. (A) Schematic representation of the fusion between the human galectin-3 (LGALS3) and bacterial AP (phoA) genes. The pLIP6GN vector was engineered and displays the phoA gene out of frame, as indicated in the top scheme, and the translated protein is truncated at aminoacid 37. After cloning, the inserted gene restores the phoA gene frameshift; thus, the translated protein contains the fusion product between the gene of interest and the phoA gene. (B) PCR of a white (pLIP6GN) and a blue colony (Gal3/AP) screened after ligation and transformation of bacteria (ctl represents a sham polymerase reaction, and no DNA was added). The fragment of the empty vector (pLIP6GN) was 195-base pairs (bp) long. Upon ligation of the 750-nucleotide (nt) fragment of LGALS3, the recombinant gene yielded a ∼948-bp-long fragment. (C) The recombinant protein was expressed in E. coli, and the periplasmic fraction was analyzed after separation on SDS-PAGE under reducing conditions for the presence of the chimera in Western blots using a monoclonal antibody raised against galectin-3. CCR2 extracts were used as positive control for galectin-3. Molecular mass markers are shown. (D) Likewise, the presence of the chimera was also analyzed using anti-AP antibodies. Extracts of bacteria transformed with pLIP6GN (negative control) or with pLIP5GN (positive control) were also analyzed. Molecular mass markers are shown.

Protein Expression and Purification

A single clone was used to transform E. coli BL21 strain. The colonies were cultured in TSB medium supplemented with 100 μg/ml ampicillin at 37C until absorbance at 600 nm reached ∼0.6. The tac promoter was then induced with 100 μM IPTG for 4 hr at 37C. Bacteria from cultures were centrifuged, and the periplasm was extracted by cold osmotic shock as previously described (Ducancel et al. 1989).

Western and Lectin Blot Analysis

The presence of the recombinant fusion protein was detected by SDS-PAGE after staining with Coomassie blue or by Western blotting, using antibodies that recognize galectin-3 and AP or alternatively using the AP substrate, 5-bromo-4-chloro-3-indolyl phosphate in the presence of nitroblue tetrazolium solution (NBT/BCIP; Boehringer Mannheim, Indianapolis, IN). After periplasmic extraction, the samples were clarified by a 20-min centrifugation at 4C, and the protein concentration was determined using the BCA protein assay reagent (Pierce Biotechnology; Rockford, IL). Equal amounts of periplasmic extracts were boiled in SDS sample buffer under reducing conditions (240 mM Tris–HCl, pH 6.8, SDS 0.8%, glycerol 40%, β-mercaptoethanol 200 mM, and bromophenol blue 0.02%) for 5 min. Samples were separated by electrophoresis on 12.5% SDS–polyacrylamide gels under reducing conditions and transferred to a polyvinylidene difluoride membrane (Millipore; Bedford, MA). After protein transfer, the membranes were incubated with 5% non-fat dry milk dissolved in PBS (10 mM sodium phosphate, 150 mM NaCl, pH 7.2) and incubated with rat monoclonal anti-galectin-3 M3/38 or with 2 μg/ml rabbit polyclonal anti-bacterial AP overnight at 4C. After three washes with 5% non-fat milk in PBS, the membranes were incubated for 1 hr with 0.5 μg/ml HRP-conjugated rabbit anti-rat IgG or HRP-conjugated anti-rabbit IgG. Following three washes, the reaction was developed using 3.75 mg DAB in Tris-buffered saline (50 mM Tris–HCl, pH 7.5, containing 150 mM NaCl) in the presence of H₂O₂ (1 μl/ml; Fluka, Seelze, Germany).

For lectin blots, protein extracts were transferred to PVDF membranes, which were blocked with PBS-1% BSA and incubated with biotin-conjugated L-PHA (Phaseolus vulgaris agglutinin) or digoxigenin-labeled GNA (Galanthus nivalis agglutinin) in PBS containing 2% BSA overnight at 4C. Next, the membranes were washed with TBS (150 mM NaCl, 50 mM Tris–HCl, pH 7.5) and incubated with the appropriate AP-conjugated secondary reagents. Following three washes with TBS and one wash with TBS containing 1 mM MgCl₂, 1 mM MnCl₂, and 1 mM CaCl₂, the membranes were developed using the AP substrate NBT/BCIP. Membranes were also incubated with 30 μg/ml gal3/AP in PBS containing 1% BSA overnight at 4C, washed with TBS, and developed as described above.

Enzyme-linked Lectin Assay (ELLA) and Statistical Analysis

ELLA was performed to evaluate the lectin and AP activity of gal3/AP. To assay the lectin activity, wells from a flat-bottom microtiter plate from Corning (Corning, NY) were coated with 10 μg/ml of laminin-1 for 1 hr at 37C and washed with PBS. Nonspecific sites were blocked with 1% BSA for 30 min at 37C and washed with PBS. Increasing concentrations of gal3/AP periplasmic extract (in the range of 0–20 μg/ml) were added to the wells either in the absence or presence of 100 mM of lactose (Sigma) and incubated overnight at 4C. After washing, because affinity constants of galectin-3 binding are in the micromolar range, the bound lectin was then cross-linked with 1% paraformaldehyde for 15 min. The wells were then washed three times with blocking solution and incubated with rat monoclonal anti-galectin-3 M3/38 for 1 hr at 37C. After three washes, 0.5 μg/ml rabbit anti-rat IgG HRP conjugate was added and incubated for 1 hr at 37C. Following washes, the freshly prepared substrate (0.4 mg/ml o-phenylenediamine in 1 ml of 0.05 M citrate–phosphate buffer pH 5.0, containing 10 ml H₂O₂ 30%) was added to each well. The reaction was run protected from the light and stopped through addition of 3 N H₂SO₄. Absorbance was read at 492 nm in a multiscan EIA reader (Bio-Rad Laboratories; Hercules, CA). Alternatively, to assay the AP activity, after incubation with gal3/AP, p-nitrophenylphosphate (1 mg/ml in diethanolamine buffer) was added. The reaction was run protected from light and, after color developed, absorbance was read at 415 nm in a multiscan EIA reader. Statistical analysis was done using two-way ANOVA (GraphPad PRISM 4 software), and the comparisons were determined significant at the 5% level (p<0.05).

Direct Binding Assay

Direct binding assay was performed to evaluate the fine specificity of gal3/AP. Diverse glycans (Glycan Array version v2.3, NIGMS Consortium for functional glycomics) were added in a 384-well HBC NeutrAvidin Black plate (ligand coating, 30 pmol/well). For the complete list of glycans used in this assay, please consult the site http://www.functionalglycomics.org/static/consortium/resources/resourcecoreh2.shtml. The plate was then washed with PBS with 0.05% Tween 20 (wash buffer) and incubated with 15 μg/ml gal3/AP in wash buffer and 1% BSA. The bound lectin was detected with anti-AP antibodies followed by incubation with Alexa 488-conjugated secondary antibodies, using a plate fluorimeter.

Tissue Staining

Sequential tissue microarray slides containing panels of human tumors of diverse origins and their normal counterparts were obtained from the Hospital A. C. Camargo, São Paulo, Brazil after approval from the local Ethics Committee and tumor bank director. Sections of buffered paraformaldehyde-fixed, paraffin-embedded thymuses or experimental murine sarcomas or melanomas were also used. Tissue sections were routinely processed, and antigen retrieval was done by heating the specimens in citrate–phosphate buffer, pH 6.0, in the microwave for 10 min. After blocking with PBS-1% BSA, the sections were incubated with 30 μg/ml gal3/AP in the blocking solution overnight at 4C, either in the absence or presence of 100 mM lactose. After washing, the reaction was developed using Fast Red in Naftol phosphate Tris–HCl buffer (1 mg/ml; Dako, Carpinteria, CA). Specimens were also stained using anti-galectin-3, anti-CD34 antibodies, and L-PHA and then developed with peroxidase-conjugated secondary reagents.

Results

Production of the Gal3/AP Hybrid Protein

Galectin-3 cDNA was successfully subcloned into the pLIP6-GN vector, giving rise to the construct shown in Figure 1A. A blue colony was screened by PCR, which confirmed the presence of a 948-base pair band corresponding to the galectin-3 gene (Figure 1B). This clone was further sequenced confirming the correct in-frame cloning of the galectin-3 cDNA. The pLIP6/gal3 clone was subsequentially used to transform E. coli BL21. After induction, the periplasmic proteins were extracted by cold osmotic shock and the expressed chimeric form of galectin-3 (gal3/AP) was further analyzed by SDS-PAGE and confirmed by Western blotting analysis using antibodies that recognize galectin-3 (Figure 1C) and AP (Figure 1D). Protein extracts from CCR2 cells were used as a control; the polypeptide recognized by M3/38 had an apparent molecular mass of 32 kDa. In gal3/AP samples and under reducing conditions, M3/38 recognized bands with apparent molecular masses of 32 and 75 kDa. The 32-kDa band is likely galectin-3 derived from gal3/AP processing (Figure 1C). The anti-AP antibody also recognized two bands with apparent molecular masses of 45 and 75, under reducing conditions. The 45-kDa band is likely AP released from gal3/AP processing. The periplasmic proteins from pLIP6-GN and pLIP5-GN were used as negative and positive controls, respectively (Figure 1D). Under non-reducing conditions, a third band with apparent molecular mass of 175 kDa was also observed in Western blots using both anti-galectin-3 and anti-AP antibodies (data not shown). It is conceivable that dimers of gal3/AP could exist, explaining the 175-kDa band.

Gal3/AP Has Both Lectin and AP Activities

Periplasmic extracts were assayed for both AP and lectin activities. Galectin-3 interacts with polylactosamines containing glycoconjugates including laminin. To examine the lectin activity of gal3/AP, ELISA plates were coated with laminin-1, and increasing concentrations of gal3/AP were incubated in the presence or absence of 100 mM lactose. Figure 2A shows that gal3/AP bound to laminin-1 in a dose-dependent manner and that this interaction was inhibited by lactose. To investigate the AP activity of the chimeric protein, p-nitrophenylphosphate was used as substrate. As shown in Figure 2B, gal3/AP partially retains its phosphatase activity comparing to the product of pLIP5-GN, used as a positive control. In these experiments, the periplasmic extract of bacteria transformed with pLIP6-GN was used as negative control. The reduced phosphatase activity of the chimera may be attributed to the inclusion of the 316-amino acid residues of Gal-3 within the N-terminal portion of the AP molecule, impairing the optimal folding of the molecule.

Gal3/AP Has the Same Specificity of Parental Galectin-3

Direct binding of gal3/AP to a panel of >190 glycans (Consortium for Functional Glycomics, Glycan plate arrays, versions 1.2 and 2.7) allowed us to determine the specificity of the chimeric lectin. Table 1 indicates the eight distinct glycans recognized by gal3/AP with higher affinity. These are essentially the same glycans recognized by the parental molecule, using the same version of the glycan plate array (galectin-3, data from 2004, available at the site of the Consortium for Functional Glycomics, http://www.functionalglycomics.org, under CFG data, Core H-glycan screening). Signal-to-noise ratio is an indirect measurement of the apparent affinity. Sialylation did not interfere with gal3/AP binding (Table 1). This was further confirmed in lectin blots using sialidase-treated protein extracts (data not shown). Note that more recently the Consortium for Functional Glycomics extended the platform using a printed array, which now includes >250 different glycans. Among them, galectin-3 bound strongly to two other glycans that were not present in the plate array used herein, namely, Galβ1–4GalNAcaα1–3(Fucα1–2)Galβ1–4GlcNAcβ and GlcNAcβ1–3Galβ1–4GlcNAcβ1–3Galβ1–4GlcNAcβ which, however, share similar determinants to blood group A (type 2) and dilactosamine (LN)₂, respectively.

Figure 2

Gal3/AP shows both lectin and AP activities. (A) Ninety-six microwell plates were coated with either laminin or BSA. After coating and blocking, wells were incubated with increasing concentrations of periplasmic extracts containing gal3/AP either in the presence or absence of lactose (LAC, 100 mM). After incubation, wells were extensively washed and bound gal3/AP was measured using a monoclonal antibody against galectin-3, followed by incubation with suitable horseradish peroxidase-conjugated secondary antibodies and then developed with o-phenylenediamine in the presence of hydrogen peroxide. Absorbance was read using 492-nm filters, using an EIA reader. (B) AP activity was measured directly on wells coated with periplasmic extracts of bacteria transformed with pLIP5GN (positive control), pLIP6GN (negative control), and the periplasmic extract containing gal3/AP. AP activity was measured using a suitable substrate for the enzyme, p-nitrophenylphosphate. Absorbance was read using 415-nm filters, using an EIA reader. Dots in both graphs indicate the means of triplicates (representative assay of at least three independent experiments). Standard errors of the means were calculated and only when errors were >5% they were indicated in the graphs, due to the scaling proportions. Curve points were analyzed statistically using two-way ANOVA, which indicated that the apparent differences were statistically significant (p<0.001).

Table 1

Gal3/AP binding specificity

Glycans	Common name	Signal-to-noise ratio
Galα1–3(Fucα1–2)Galβ1–4GlcNAc	B (type 2)	25.93
Galβ1–4GlcNAcβ1–3Galβ1–4GlcNAcβ1–3Galβ1–4GlcNAc	(LN)₃	25.65
GalNAcα1–3(Fucα1–2)Galβ1–4GlcNAcβ	A (type 2)	19.99
Neu5Acα2–3Galβ1–4GlcNAcβ1–3Galβ1–4GlcNAcβ1–3Galβ1–4GlcNAcβ	3′Sia(LN)₃	19.65
Galβ1–4GlcNAcβ1–3Galβ1–4GlcNAcβ	(LN)₂	12.63
Fucα1–2Galβ1–4GlcNAcβ1–3Galβ1–4GlcNAc	2′Fuc(LN)₂	10.19
Galβ1–4GlcNAcβ1–3Galβ1–4Glcβ	LNnT	7.45
Neu5Acα2–6Galβ1–4GlcNAcβ1–3Galβ1–4GlcNAcβ	6′Sia(LN)₂	7.12

Gal3/AP fine specificity was determined using a glycan plate array composed of >180 different glycans (versions 1.2 and 2.7). Specific binding of Gal3/AP was observed in eight distinct glycans ordered by signal-to-noise ratio, all derivatives of lactosamine structures (LN) and shown in bold in the first column. The binding profile was identical to non-engineered human galectin-3. A complete list of all glycans analyzed can be found at the Consortium for Functional Glycomics (CFG) web page, CFG data for glycan screening.

Gal3/AP Recognition Depended at Least in Part on the N-linked Oligosaccharides of Different Glycoproteins

Gal3/AP was useful in ligand blottings, as shown in Figure 3. The pattern of gal3/AP binding was compared with L-PHA binding in protein extracts derived from established cell lines. To evaluate the binding of gal3/AP to N-linked oligosaccharides, the sarcoma cell lines CCR2 and Σ12 were treated with 1 mM of dMN, an inhibitor of α-mannosidase I. After the treatment, protein extracts were separated in 10% SDS–polyacrylamide gels under reducing conditions, transferred onto PVDF membrane, and analyzed with L-PHA, gal3/AP, and GNA. L-PHA recognizes β1–6-GlcNAc-bearing glyco-proteins and was used as positive control. GNA recognizes high-mannose N-linked oligosaccharides, which were exposed after dMN treatment and, therefore, were used as controls for the treatment with dMN. Two major glycoproteins of apparent molecular masses of 195 and 82 kDa were decreased after dMN treatment as revealed in L-PHA and gal3/AP lectin blot. In contrast, one major band of 160 kDa increased in GNA lectin blot (Figure 3A).

In a second set of experiments, B16F10 and Σ12 cells were treated with 1 μg/ml of swainsonine (SW), an inhibitor of mannosidase II, for 48 hr. After that, protein extracts from B16F10 and Σ12 cells were subjected to lectin blot analyses, using L-PHA and gal3/AP (Figure 3B). Several bands were recognized by L-PHA in B16F10 extracts. Major bands included a polydisperse band of 120–140 kDa and an 80-kDa band. The 120-to 140-kDa polydisperse band was also found in Σ12 cell extracts. This band was also recognized by Gal3/AP. Upon SW treatment, a significant decrease in the binding of both L-PHA and Gal3/AP was found. The 80-kDa band was no longer identified after SW treatment in B16F10 cells. On the other hand, two smaller bands of 50 and 60 kDa apparent molecular mass were observed upon SW treatment. It is clear from both approaches that L-PHA and gal3/AP binding may be similar but not identical and are at least in part dependent on N-linked glycosylation. Gal3/AP binding was abolished by co-incubation of the lectin with 100 mM lactose (data not shown), as observed in direct binding assays using laminin as a galectin-3 ligand (Figure 2A).

Figure 3

L-PHA and gal3/AP recognition patterns are similar but not identical. We compared the binding profiles of both leukoagglutinin from Phaseolus vulgaris (L-PHA) and gal3/AP using lectin blots of selected cell lines (the murine fibrosarcoma cell lines Σ12 and CCR2 and the murine melanoma cell line, B16F10). Cells were previously treated (+) or not (−) with the mannosidase inhibitors deoxymannojirimycin (DMN), an α-mannosidase I inhibitor (A) and swainsonine (SW), an α-mannosidase II inhibitor (B). DMN treatment was ascertained using Galanthus nivalis agglutinin (GNA), a plant lectin with specificity toward high-mannose-containing glycans. SW treatment was verified by loss of L-PHA binding. In addition to not being identical, L-PHA and gal3/AP binding sensitivity to SW was also different in the two cell lines studied.

Expression of Galectin-3 Ligands in Different Types of Tumors by Tissue Assay

Gal3/AP could be used to identify galectin-3 ligands in situ. Paraffin-embedded murine thymuses (see example in Figures 4A–4D) and sarcomas (derived from CCR2 murine cell line, Figures 4E–4H) were used to compare the binding pattern of the plant lectin L-PHA (Figures 4B and 4F) and gal3/AP (Figure 4C, 4D, 4G, and 4H). Gal3/AP binding was abolished by coincubation of the lectin with 100 mM lactose (data not shown and supplemental figures, SF1–SF9), as observed in direct binding assays using laminin as a galectin-3 ligand (Figure 2A). Presence of galectin-3 is also shown in Figure 4 (A, E).

Figure 4

Lectin histochemistry using Gal3/AP indicates that not all L-PHA-positive cells bear galectin-3 ligands. Murine thymus (A–D) and experimental murine sarcomas (E–H) were analyzed regarding the distribution of galectin-3-positive cells (A, E), L-PHA-reactive cells (B, F), and gal3/AP-reactive cells (C, D, G, H). (Left column) Galectin-3 was found in scattered cells both in the thymic medulla (M) and cortex (C). L-PHA stained mainly medullary structures and scattered cells in the cortex and subcapsullary regions. On the other hand, gal3/AP recognized mostly cortical cells (niches of CD4⁺CD8⁺ cells) and scattered cells in the medulla, as seen in C and D. Note that the vascular structure shown in the medulla in D was not recognized by gal3/AP. In the case of experimental sarcomas (right column), sarcoma cells (S) infiltrated muscular fibers (m), displaying a particular pattern of invasion, as sarcoma cells seemed to migrate through the basement membranes of muscle fibers. Sarcoma cells accumulated galectin-3 mainly in the nucleus of the tumor cells (E). These cells reacted strongly with L-PHA, which stained not only the cells but also the extracellular matrix (F). Fewer sarcoma cells were recognized by gal3/AP (G, H). Bars: A–C = 100 μm; D–G = 25 μm; H = 12.5 μm.

In the murine thymus, cells expressing galectin-3 are scattered in cortex and medulla. Whereas L-PHA structures are found in both thymic compartments, especially in the vascular structures in the medulla, gal3/AP bound mainly cortical cells (Figure 4C) and a few cells in the medulla (Figure 4D). De novo expression of sialyltransferases is a common hallmark of thymocyte differentiation (Wu et al. 1997; Starr et al. 2003). As mentioned above, loss of galectin-3 binding was not due to masking of galectin-3 ligands by the addition of sialic acid residues because treatment of thymocyte extracts with sialidase did not expose novel gal3/AP binding sites (data not shown). Experimental sarcomas (Figures 4E–4H) express galectin-3 (Figure 4E) and migrate onto basement membranes of muscle fibers, as discussed elsewhere (Jasiulionis et al. 1996) and indicated in Figure 4H (note that Gal3/AP-stained sarcoma cells are adhered to muscle fibers). In this example, gal3/AP binding was not as evident as L-PHA binding, although as shown in Figures 4F–4H, infiltrating sarcoma cells stained with both plant and animal lectins.

Specimens from different human tumors were also analyzed using a tissue microarray. Examples of tissue staining by Gal-3/AP that were more representative are shown in Figure 5, which depicts examples of staining from breast carcinomas (Figures 5A and 5B), prostate carcinomas (Figures 5C and 5D), a glioblastoma (Figure 5E), and a melanoma (Figure 5F). Strong immunoreactivity was detected in the apical portion of well-differentiated breast carcinomas, including in the lumen secretion (Figure 5A). A trend to lose gal3/AP binding was observed in poorly differentiated tumors (Figure 5B). A similar trend was observed in prostate cancer (Figure 5C illustrates a well-differentiated tumor; Figure 5D illustrates a poorly differentiated tumor). Stromal reactivity was intense and found either in vascular elements (Figure 5D) or reactive glial cells (as indicated in the glioblastoma, arrow in Figure 5E). Heterogeneity of gal3/AP binding was observed in human melanomas, as illustrated in Figure 5F (arrow indicates an example of a strongly reactive cell in an infiltrated microenvironment). Supplemental figures illustrate the broad pattern of galectin-3 ligand distribution in a selected variety of human tumors, including squamous cell carcinoma, breast, prostate, pancreas carcinomas, melanomas, neuroendocrine tumors, neuroblastomas, and glioblastomas.

In murine melanomas (Figure 6), gal3/AP bound both vascular structures and infiltrating stromal cells. Gal3/AP binding (Figures 6B and 6D) was comparable to anti-CD34 antibodies, as illustrated in Figures 6A and 6C. In this regard, the probe we have developed could be used to determine microvascular density within experimental tumors. Moreover, a subset of dendritic-like stromal cells (Figure 6D) also stained intensely with gal3/AP.

Figure 5

Human tumors are recognized by gal3/AP. Examples of the heterogeneous reactivity of gal3/AP in different human cancers. Breast (A, B) and prostate (C, D) adenocarcinomas, glioblastoma (E), and melanoma (F) specimens are illustrated. Whereas gal3/AP stained the apical surfaces of epithelial cells in well-differentiated adenocarcinomas (A, C), this reactivity was virtually lost in poorly differentiated tumors (B, D). Note that microvessels were also stained in D. In the case of glioblastomas, tumor cells were not recognized by gal3/AP, whereas reactive glial cells were strongly stained (arrow in E). In the case of melanoma tumors (example in F), gal3/AP binding was highly heterogeneous with a strong reactivity in infiltrating cells (arrow). Bar = 50 μm.

Discussion

We have described here the production, expression, and some applications of gal3/AP, a hybrid molecule displaying both the carbohydrate binding properties of galectin-3 and enzymatic activity of AP. The binding profile of this chimeric molecule was compared with the binding of the plant lectin L-PHA. Although the binding specificities of L-PHA and galectin-3 are similar at the oligosaccharide level (Cummings and Kornfeld 1982; Sato and Hughes 1992; Demetriou et al. 2001), we showed here that neither glycoprotein profiling nor in situ binding of each lectin was identical. Therefore, it seems incorrect to use L-PHA and galectin-3 staining data interchangeably. As the probe presented here is derived from galectin-3 itself, it is a more adequate tool for pathophysiological studies on the roles of galectin-3 than the plant lectin. Gal3/AP will be useful to identify the binding patterns of galectin-3 and will be useful for the in situ determination of galectin-3 ligand distribution. This tool is an alternative to biotinylated lectins, which had been widely used to describe the distribution pattern of glycoconjugates in normalcy and malignancy. Indeed, biotinylated galectin-3 had been successfully used by different groups, following the pioneering work of Gabius and colleagues (Choufani et al. 1999; Plzak et al. 2001). Gal3/AP is an effective alternative to biotinylated galectin-3; the former, however, can be produced in a single step. As no chemical modifications are necessary for the generation of the chimeric probe, it is anticipated that Gal3/AP-specific activity would be rather constant from batch to batch, in addition to allowing a direct determination of galectin-3 ligands in situ, thus overcoming the potential problem of loss of specificity due to the use of secondary reagents for development of the reaction. Furthermore, Gal3/AP represents a suitable alternative for studying the distribution of galectin-3 ligands in tissues where endogenous biotin levels are high.

Figure 6

Gal3/AP is a useful probe for analysis of tumor microenvironmental cells. (A–D) Tumor-associated vascular structures which were recognized by anti-CD34 (A, C) were also recognized by gal3/AP (B, D). Dendritic-like cells within experimental melanomas were strongly stained with gal3/AP (bold arrow in B, D). Bar = 25 μm.

Immunopurified molecules can be probed directly with the chimeric galectin-3. Binding of the chimeric probe to immobilized glycoproteins in lectin blots has been used recently to identify different glycoforms of integrins as ligands for galectin-3 (Chammas and Bellis, unpublished data). The lectin blot and ligand overlay assays do not favor conformation-dependent protein–protein interactions, although there are a few examples of peptide–protein receptor interactions in ligand blottings in the literature (Chammas et al. 1994b). It seems likely that most of the binding partners of galectin-3 revealed in lectin blots are glycoproteins, and that the oligosaccharide residues present in the blotted glycoproteins are the actual determinants of galectin-3 binding. Indeed, lactose inhibited gal3/AP binding to blotted proteins (data not shown), as it did in ELISA assays (Figure 2A). Due to galectin-3 specificity, most proteins revealed in lectin blots are likely to be either cell surface or extracellular matrix glycoproteins. The finding that the mannosidase inhibitors, dMN and SW, led to a decreased binding of gal3/AP (Figure 3) corroborates the notion that N-linked glycans serve as galectin-3 ligands (Cheung et al. 1985; Partridge et al. 2004; Lagana et al. 2006). O-linked glycans, such as those present in CD43 and CD45, could also be recognized by galectin-3. On the other hand, intracellular glycoproteins do not usually present disaccharide structures, except in the case of cytokeratin, as described by Goletz et al. (1997).

There is increasing interest in determining the apparently non-glycosylated intracellular partners of galectin-3. Two hybrid systems led to the identification of molecules such as gemin 1 and 4 and β-catenin as galectin-3 binding molecules, among others (Park et al. 2001; Shimura et al. 2004). Optimal conditions for binding of gal3/AP to intracellular proteins may be determined in enzyme-linked lectin assays, a useful application of this chimeric molecule. These assays are likely to be done under reducing conditions, as those found in the cytoplasm.

The most direct application of the molecule described here is its use in direct lectin histochemistry. The involvement of galectin-3 in inflammation, development of both innate and adaptive immune responses, and tumor progression is anticipated by several lines of evidence and has been reinforced by studies using galectin-3 null mice (Colnot et al. 1998; Hsu et al. 2000; Bernardes et al. 2006; Silva-Monteiro et al. 2007). Although some of these roles may be exclusively due to the functions of intracellular galectin-3, some will involve its lectin function. The chimeric probe will aid in the identification and a more precise description of tissue microenvironments where galectin-3 may play a role.

In the murine thymus, for example, most of the ligands for galectin-3 are confined to the cortical thymocytes, different from what was observed to L-PHA staining. We have shown that extracellular galectin-3 acts as a de-adhesion molecule disrupting the interactions between thymocytes and thymic microenvironmental cells, such as the cortical thymic epithelial cells found in the thymic nurse complexes (Villa-Verde et al. 2002). Data shown in Figure 4D suggest that most of the galectin-3 ligands are in immature thymocytes found in the thymic cortex. This notion was recently confirmed by independent groups of experiments. On one hand, we have shown that galectin-3 mainly affects migration of CD4⁺CD8⁺ cells (Silva-Monteiro et al. 2007), whereas Baum's group demonstrated that galectin-3 induces CD4⁻CD8⁻ cell death (Stillman et al. 2006). In experimental sarcomas, the probe was useful to illustrate the pattern of dysfunctional migration of sarcoma cells on laminin-rich muscle basement membranes (Figures 4E–4H).

However, the higher impact of the use of this probe will be on studies on the clinical significance of a specific pattern of aberrant glycosylation, namely, β1–6 branching of N-linked glycans. Although it is quite clear that several tumors accumulate glycoproteins bearing β1–6-branched N-linked oligosaccharides, the precise function of this altered pattern of glycosylation in glycoprotein function remains elusive (Dennis and Laferte 1989; Fernandes et al. 1991; Chammas et al. 1994a; Handerson and Pawelek 2003; Handerson et al. 2005; Siddiqui et al. 2005). An extremely interesting hypothesis on the role of this glycosylation pattern was revisited by Dennis (Partridge et al. 2004), based on a model proposed by Childs and Feizi, among others, in the 1980s. In this model, glycoproteins would exist as lattices on the cell surface. Maintenance of these lattices would depend on extracellular glycan-binding proteins such as galectin-3. Complexes of glycoproteins and lectins would render cells more sensitive to growth factors, whose interaction with their cognate receptors usually lead to receptor dimerization/oligomerization. If this is correct, expression of galectin-3 and its ligands may predict the prognosis of tumors. So far, most of the information on the presence of putative ligands for galectin-3 is based on the tumor reactivity to L-PHA. Determination of galectin-3 ligands using gal3/AP may represent a more suitable approach to this problem. As we have shown here, gal3/AP was useful for staining tissue mi-croarrays. Staining of specific tumor collections such as breast and prostate (see examples in Figure 5) and the correlation of the data obtained with clinical information will be useful to determine the significance of the presence of ligands for galectin-3 in tumor cells. Gal3/AP staining evidenced the loss of polarity in breast and prostate carcinomas. This event is a frequent finding in carcinoma progression and can be followed by the presence of tumor-associated antigens in the sera of patients. Examples for these antigens include secretion of CEA, which is a galectin-3 ligand (Cvejic et al. 2000; Wojciechowicz et al. 2000), and several sialomucins (such as CA125 and CA19.9), which may also bear polylactosamines recognizable by galectin-3. Gal3/AP will also be useful for the detection of aberrantly glycosylated glycoproteins in the sera of patients, using quantitative AP-based assays.

The survey in different tumors clearly indicated that not only tumor cells, but also microenvironmental cells as infiltrating leukocytes, express galectin-3 ligands (Figure 5 and Figure 6). Positive identification of these ligands is warranted, and gal3/AP will be a useful tool for this objective. Moreover, gal-3/AP stained vascular structures in tumor sections as well as the commonly used antibodies anti-CD31 and anti-CD34 (Figure 6). Accordingly, recent findings indicate that galectin-3 participates in tumor angiogenesis (Nangia-Makker et al. 2000; Fukushi et al. 2004; Shekhar et al. 2004) This finding will be useful to determine the microvascular density of tumors that do not express CD34 or in tumors that aberrantly express CD34, as is the case for experimental renal carcinomas (data not shown).

Finally, as Gal3/AP is a recombinant chimeric probe, its production in E. coli renders it a cost-effective tool for a variety of enzymatic assays including in situ identification of galectin-3 ligands and will help to determine the biological functions of this animal lectin.

Footnotes

Acknowledgements

This work was funded by FAPESP (Center for Cell-based Therapy Research, 1998/14247-6) and CNPq grants. The glycan-array analysis was conducted by the Protein–Carbohydrate Interaction Core (H) of The Consortium for Functional Glycomics funded by the National Institute of General Medical Sciences (Grant GM62116).

We are grateful to Dr. Frederic Ducancel, CEA-Saclay, Gif-sur-Yvette, France, for providing the vectors used in this work and to Dr. Paulo Lee Ho, Centro de Biotecnologia do Instituto Butantan, for sequencing the constructs. We thank the Core H staff, Ms. Angela Lee, and Mrs. Carole Davis for their help in conducting the assays.

References

Agrwal

Sun

Wang

(1993) Carbohydrate-binding protein 35. J Biol Chem 268:14932–14939

Akahani

Nangia-Makker

Inohara

Kim

Raz

(1997) Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 57:5272–5276

Almkvist

Dahlgren

Leffler

Karlsson

(2004) Newcastle disease virus neuraminidase primes neutrophils for stimulation by galectin-3 and formyl-Met-Leu-Phe. Exp Cell Res 298:74–82

Bernardes

Silva

Ruas

Mineo

Loyola

Hsu

Liu

. (2006) Toxoplasma gondii infection reveals a novel regulatory role for galectin-3 in the interface of innate and adaptive immunity. Am J Pathol 168:1910–1920

Chammas

Cella

Marques

Brentani

Hynes

Franco

(1994a) Correspondence re: B. Fernandes et al., β1–6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. Cancer Res 51: 718–723, 1991. Cancer Res 54: 306–308

Chammas

Jasiulionis

Jin

Villa-Verde

Reinhold

(1994b) Carbohydrate-binding proteins in cell-matrix interactions. Braz J Med Biol Res 27:2169–2179

Cheung

Saarinen

Neely

Landmeier

Donovan

Coccia

(1985) Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 45:2642–2649

Choufani

Nagy

Saussez

Marchant

Bisschop

Burchert

Danguy

. (1999) The levels of expression of galectin-1, galectin-3, and the Thomsen-Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers. Cancer 86:2353–2363

Colnot

Ripoche

Milon

Montagutelli

Crocker

Poirier

(1998) Maintenance of granulocyte numbers during acute peritonitis is defective in galectin-3-null mutant mice. Immunology 94:290–296

10.

Cortegano

del Pozo

Cordaba

de Andrés

Gallardo

del Amo

Arrieta

. (1998) Galectin-3 down-regulates IL-5 gene expression on different cell types. J Immunol 161:385–389

11.

Cummings

Kornfeld

(1982) Characterization of the structural determinants required for the high affinity interaction of asparagine-linked oligosaccharides with immobilized Phaseolus vulgaris leukoagglutinating and erythroagglutinating lectins. J Biol Chem 257:11230–11234

12.

Cvejic

Savin

Golubovic

Paunovic

Tatic

Havelka

(2000) Galectin-3 and carcinoembryonic antigen expression in medullary thyroid carcinoma: possible relation to tumour progression. Histopathology 37:530–535

13.

Demetriou

Granovsky

Quaggin

Dennis

(2001) Negative regulation of T-cell activation and autoimmunity by Mgat5 N- glycosylation. Nature 409:733–739

14.

Demetriou

Nabi

Coppolino

Dedhar

Dennis

(1995) Reduced contact-inhibition and substratum adhesion in epithelial cells expressing GlcNAc-transferase V. J Cell Biol 130:383–392

15.

Dennis

Laferte

(1989) Oncodevelopmental expression of—GlcNAcβ1-6Manα1-6Manβ1—branched asparagine-linked oligosaccharides in murine tissues and human breast carcinomas. Cancer Res 49:945–950

16.

Dong

Hughes

(1997) Macrophage surface glycoproteins binding to galectin-3 (Mac-2-antigen). Glycoconj J 14:267–274

17.

Ducancel

Boulain

Tremeau

Menez

(1989) Direct expression in E. coli of a functionally active protein A–snake toxin fusion protein. Protein Eng 3:139–143

18.

Fernandes

Sagman

Auger

Demetrio

Dennis

(1991) β1–6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. Cancer Res 51:718–723

19.

Feuk-Lagerstedt

Jordan

Leffler

Dahlgren

Karlsson

(1999) Identification of CD66a and CD66b as the major galectin-3 receptor candidates in human neutrophils. J Immunol 163:5592–5598

20.

Fukumori

Takenaka

Yoshii

Kim

Hogan

Inohara

Kagawa

. (2003) CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res 63:8302–8311

21.

Fukushi

Makagiansar

Stallcup

(2004) NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and α3β1 integrin. Mol Biol Cell 15:3580–3590

22.

Gillet

Ducancel

Pradel

Leonetti

Menez

Boulain

(1992) Insertion of a disulfide-containing neurotoxin into E. coli alkaline phosphatase: the hybrid retains both biological activities. Protein Eng 5:273–278

23.

Glinsky

Rittenhouse-Olson

Huflejt

Glinskii

Deutscher

Quinn

(2001) The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res 61:4851–4857

24.

Goletz

Hanisch

Karsten

(1997) Novel αGalNAc containing glycans on cytokeratins are recognized invitro by galectins with type II carbohydrate recognition domains. J Cell Sci 110:1585–1596

25.

Gong

Honjo

Nangia-Makker

Hogan

Mazurak

Bresalier

Raz

(1999) The NH₂ terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells. Cancer Res 59:6239–6245

26.

Handerson

Camp

Harigopal

Rimm

Pawelek

(2005) β1,6-branched oligosaccharides are increased in lymph node metastases and predict poor outcome in breast carcinoma. Clin Cancer Res 11:2969–2973

27.

Handerson

Pawelek

(2003) β1,6-branched oligosaccharides and coarse vesicles: a common, pervasive phenotype in melanoma and other human cancers. Cancer Res 63:5363–5369

28.

Hsu

Yang

Pan

Salomon

Fung-Leung

Liu

(2000) Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am J Pathol 156:1073–1083

29.

Inohara

Akahani

Koths

Raz

(1996) Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res 56:4530–4534

30.

Jasiulionis

Chammas

Ventura

Travassos

Brentani

(1996) α6-β1 integrin, a major cell surface carrier of β1–6 branched oligosaccharides, mediates migration of EJ-ras-transformed fibro-blasts on laminin-1 independently of its glycosylation state. Cancer Res 56:1682–1689

31.

Khaldoyanidi

Glinsky

Sikora

Glinskii

Mossine

Quinn

Glinsky

. (2003) MDA-MB-435 human breast carcinoma cell homo- and heterotypic adhesion under flow conditions is mediated in part by Thomsen-Friedenreich antigen-galectin-3 interactions. J Biol Chem 278:4127–4134

32.

Kim

Mayer

Nachtigal

(2003) Galectin-3 expression in macrophages is signaled by Ras/MAP kinase pathway and up-regulated by modified lipoproteins. Biochim Biophys Acta 1641:13–23

33.

Lagana

Goetz

Cheung

Raz

Dennis

Nabi

(2006) Galectin binding to Mgat5-modified N-glycans regulates fibronectin matrix remodeling in tumor cells. Mol Cell Biol 26:3181–3193

34.

Lin

Pestell

Raz

Kim

(2002) Galectin-3 enhances cyclin D₁ promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells. Oncogene 21:8001–8010

35.

Liu

Rabinovich

(2005) Galectins as modulators of tumour progression. Nat Rev Cancer 5:29–41

36.

Mazurek

Sun

Price

Ramdas

Schober

Nangia-Makker

Byrd

(2005) Phosphorylation of galectin-3 contributes to malignant transformation of human epithelial cells via modulation of unique sets of genes. Cancer Res 65:10767–10775

37.

Mengwasser

Liu

Sleeman

(2002) Galectin-3 is strongly up-regulated in nonapoptosing mammary epithelial cells during rat mammary gland involution. Glycobiology 12:129–134

38.

Muller

Lamoure

Le Du

Cattolico

Lajeunesse

Lemaitre

Pearson

. (2001) Improving Escherichia coli alkaline phosphatase efficacy by additional mutations inside and outside the catalytic pocket. Chembiochem 2:517–523

39.

Nangia-Makker

Honjo

Sarvis

Akahani

Hogan

Pienta

Raz

(2000) Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 156:899–909

40.

Ochieng

Warfield

(1995) Galectin-3 binding potentials of mouse tumor EHS and human placental laminins. Biochem Biophys Res Commun 217:402–406

41.

Ochieng

Warfield

Green-Jarvis

Fentie

(1999) Galectin-3 regulates the adhesive interaction between breast carcinoma cells and elastin. J Cell Biochem 75:505–514

42.

Park

Voss

Grabski

Wang

Patterson

(2001) Association of galectin-1 and galectin-3 with Gemin4 in complexes containing the SMN protein. Nucleic Acids Res 29:3595–3602

43.

Partridge

Le Roy

Di Guglielmo

Pawling

Cheung

Granovsky

Nabi

. (2004) Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science 306:120–124

44.

Plzak

Smetana

Jr Hrdlickova

Kodet

Holikova

Liu

Dvorankova

. (2001) Expression of galectin-3-reactive ligands in squamous cancer and normal epithelial cells as a marker of differentiation. Int J Oncol 19:59–64

45.

Sano

Hsu

Apgar

Kuwabara

Yamanaka

Hirashima

. (2000) Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J Immunol 165:2156–2164

46.

Sasaki

Brakebusch

Engel

Timpl

(1998) Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds beta1 integrins, collagens and fibronectin. EMBO J 17:1606–1613

47.

Sato

Hughes

(1992) Binding specificty of a baby hamster kidney lectin for H type I and II chains, polylactosamine glycans, and appropriately glycosylated forms of laminin and fibronectin. J Biol Chem 267:6983–6990

48.

Shekhar

Nangia-Makker

Tait

Miller

Raz

(2004) Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions. Am J Pathol 165:1931–1941

49.

Shimura

Takenaka

Tsutsumi

Hogan

Kikuchi

Raz

(2004) Galectin-3, a novel binding partner of β-catenin. Cancer Res 64:6363–6367

50.

Siddiqui

Pawelek

Handerson

Lin

Dickson

Rimm

Camp

(2005) Coexpression of β1,6-N-acetylglucosaminyl-transferase V glycoprotein substrates defines aggressive breast cancers with poor outcome. Cancer Epidemiol Biomarkers Prev 14:2517–2523

51.

Silva-Monteiro

Lorenzato

Nihei

Junqueira

Rabinovich

Hsu

Liu

F-T

. (2007) Altered expression of galectin-3 induces cortical thymocyte depletion and premature exit of immature thymocytes during Trypanosoma cruzi infection. Am J Pathol 170:546–556

52.

Sivridis

Agnantis

(1996) The loss of lectin reactivity from human endometrium is a feature of malignant change. Pathol Res Pract 192:989–997

53.

Starr

Daniels

Lucido

Jameson

Hogquist

(2003) Thymocyte sensitivity and supramolecular activation cluster formation are developmentally regulated: a partial role for sialylation. J Immunol 171:4512–4520

54.

Stillman

Hsu

Pang

Brewer

Johnson

Liu

Baum

(2006) Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J Immunol 176:778–789

55.

Suzuki

Nozawa

Kawaguchi

Abe

(1999) Phaseolus vulgaris leukoagglutinating lectin-binding reactivity in human diffuse large B-cell lymphoma and its relevance to the patient's clinical outcome: lectin histochemistry and lectin blot analysis. Pathol Int 49:874–880

56.

Swarte

Mebius

Joziasse

van den Eijnden

Kraal

(1998) Lymphocyte triggering via L-selectin leads to enhanced galectin-3-mediated binding to dendritic cells. Eur J Immunol 28:2864–2871

57.

Takenaka

Fukumori

Yoshii

Oka

Inohara

Kim

Bresalier

. (2004) Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol 24:4395–4406

58.

Uhlen

Moks

(1990) Gene fusions for purpose of expression: an introduction. Methods Enzymol 185:129–143

59.

Villa-Verde

Silva-Monteiro

Jasiulionis

Farias-de-Oliveira

Brentani

Savino

Chammas

(2002) Galectin-3 modulates carbohydrate-dependent thymocyte interactions with the thymic microenvironment. Eur J Immunol 32:1434–1444

60.

Vray

Camby

Vercruysse

Mijatovic

Bovin

Ricciardi-Castagnoli

Kaltner

. (2004) Up-regulation of galectin-3 and its ligands by Trypanosoma cruzi infection with modulation of adhesion and migration of murine dendritic cells. Glycobiology 14:647–657

61.

Wojciechowicz

Park

Datta

Paty

(2000) CEA is the major PHA-L-reactive glycoprotein in colon carcinoma cell lines and tumors: relationship between K-ras activation and β1–6 branching of N-linked carbohydrate on CEA. Biochem Biophys Res Commun 273:147–153

62.

Punt

Granger

Sharrow

Kearse

(1997) Developmentally regulated expression of peanut agglutinin (PNA)-specific glycans on murine thymocytes. Glycobiology 7:349–356

63.

Yamamoto

Swoger

Greene

Saito

Hurh

Sweeley

Leestma

. (2000) β1,6-N-acetylglucosamine-bearing N-glycans in human gliomas: implications for a role in regulating invasivity. Cancer Res 60:134–142

64.

Yamaoka

Kuwabara

Frigeri

Liu

(1995) A human lectin, galectin-3 (epsilon bp/Mac-2), stimulates superoxide production by neutrophils. J Immunol 154:3479–3487

65.

Yang

Hill

Hsu

Liu

(1998) Role of the carboxyl-terminal lectin domain in self-association of galectin-3. Biochemistry 37:4086–4092